

FLORIDA MEDICAID Prior Authorization Orfadin[®]

(Maximum Length of Therapy is 12 Months)

Note: Form must be completed in full. An incomplete form may be returned.

Recipient's Medicaid ID #	Date of Birth (MM/DD/YYY)
Recipient's Full Name	
Prescriber's Full Name	
Prescriber License # (ME, OS, ARNP, PA)	
Prescriber Phone Number	Prescriber Fax Number
Pharmacy Name	
Pharmacy Medicaid Provider #	
Pharmacy Phone Number	Pharmacy Fax Number
1. Is the patient's diagnosis hereditary tyrosinemia type I? O Yes O No	
2. Are the dietary restrictions of tyrosine and	phenylalanine alone sufficient to maintain the urinary succinylacetone at or
below detectable levels? O Yes	D No
3. Is this patient currently placed on a liver tra	ansplantation waiting list? O Yes O No
4. In your opinion, will this patient likely beco	me a candidate for liver transplantation within the next year?
O Yes O No	
5. The patient's current weight is	
Prescriber's Signature:	Date:
REQUIRED FOR REVIEW: Copies of medical records (i.e., diagnostic evaluations and recent chart notes), a copy of the original prescription, and the most recent copies of related labs. The provider must retain copies of all documentation for five years.	

Fax Information to:



Pharmacy Provider Services Fax: 855-825-2717 Phone: 1-800-617-5727



Review Criteria

- 1. If the patient can be maintained on dietary restrictions alone, Orfadin[®] is not approved. (If the answer to question two is YES, do not approve.)
- 2. If the patient is on a liver transplantation list, approval period is only for six months.
- 3. If in the physician's opinion, the patient will become a liver transplant candidate within the next year, the approval period is only six months.
- 4. All other approvals are for a one-year period.
- 5. Limit the dose to 2mg per Kg plus a 25 percent growth factor.
- 6. Orfadin is packaged in a high density (HD) polyethylene container of <u>60 capsules</u> and cannot be repackaged and dispensed in a different container.